Vinge advises Bridgepoint Development Capital III and Bridgepoint Europe VI (”Bridgepoint”), founders as well as the other shareholders in connection with Cinven, an international private equity firm, acquiring a significant stake in Vitamin Well Group (“Vitamin Well”) and thereby becoming the new lead investor, while Bridgepoint, founders and the other shareholders will retain significant minority stakes following the transaction.

Vitamin Well, founded in 2008 and headquartered in Stockholm, is a fast-growing functional foods and beverage group offering premium products for health-conscious and active consumers. Today, the group has approximately 500 employees and a broad multi-brand product portfolio, including the core brands Vitamin Well (vitamin and mineral-enriched beverages), NOCCO (energy drinks) and Barebells (protein bars and shakes), which are sold internationally in more than 40 markets.

The transaction is subject to regulatory approvals.

Vinge’s team consisted mainly of Daniel Rosvall, Samra Tesser, Carl Fredrik Wachtmeister, Robin Fagerström, Sara Passandideh and Lovisa Jonassen (M&A), Albert Wållgren, Karl-Gustaw Tobola and Josef Groow (Banking and Finance), Ebba Svenburg and Jonna Skog (Employment), Arvid Axelryd (Intellectual Property), Karolina Cohrs (Real Estate), Christoffer Nordin, Martin Boström, Carla Zachariasson and Arthur Kinski (Commercial Agreements, IT and GDPR) David Olander, Lovisa Lewin and Hampus Peterson (EU and FDI Regulatory) Anders Leissner, Tyra von Mentzer and Gulestan Ali (Compliance), Jessica Öijer, Cecilia Loctander and Christoffer Widström (Transaction Support Coordinators).

Related

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026

Vinge advises Studentbostäder i Norden AB (publ) in connection with its issuance of bonds in an amount of SEK 500 million and its early redemption of outstanding bonds

Vinge has advised Studentbostäder i Norden AB (publ) in connection with its issuance of senior unsecured bonds in an amount of SEK 500 million (within a framework of SEK 750 million) and in parallel with the company's voluntary early redemption of previously issued bonds.
March 12, 2026